Skip to main content

Table 1 Target coverage in the nominal and worst-case plans

From: Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial

 

Vprescription dose(%)

D95(Gy)

 

To PTV (nominal plan)

To CTV (worst-case)

Difference

To PTV (nominal plan)

To CTV (worst-case)

Difference

Patient 1

90.7

89.1

1.6

72.0

70.9

1.1

Patient 2

93.9

93.4

0.5

73.4

73.4

0

Patient 3

95.6

91.1

3.5

74.2

72.7

1.5

Patient 4

90.0

85.6

4.4

69.2

66.9

2.3

Patient 5

81.0

78.0

3.0

68.9

65.4

3.5

Patient 6

88.1

83.0

4.1

67.3

64.8

2.5

Patient 7

93.0

91.0

2.0

72.0

70.8

1.2

Patient 8

81.1

78.5

2.6

69.4

67

2.4

Patient 9§

      

1st plan

95.1

93.1

2.0

44.0

43.6

0.4

2nd plan

97.6

93.6

4.0

30.3

29.8

0.5

  1. Abbreviations: V prescription dose volume (in percent) receiving at least the prescription dose, D 95 the minimum dose received by 95% of the target, PTV planning target volume, CTV clinical target volume.
  2. §Two plans were prepared for this patient during the radiation therapy (“adaptive planning”); the prescribed doses were 44 Gy in the first plans and 30 Gy in the second.